{"slug":"recovery-stack-gabapentin","verification":{"valid":true,"entries":16,"head":"4c79d3343efca6c42ad63e3e4894afe1494dba8d2ade93f37f3f26130920b9ed"},"energy":{"passes":16,"tokens_in":5254,"tokens_out":1670,"tokens_total":6924,"cost_usd":0,"models":{"grok/grok-4.3":2,"kimi/moonshot-v1-8k":1,"system/audit-repair":7,"gemini/gemini-2.5-flash":1,"grok-4.3":2,"repair":1,"fill-slots":1,"owner":1},"head":"4c79d3343efca6c42ad63e3e4894afe1494dba8d2ade93f37f3f26130920b9ed"},"provenance":[{"ts":"2026-06-29T09:03:07.069Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):\nBPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).\nTB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.\nARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.\nSemax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.\nSelank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).\nPT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).\nDSIP — Delta Sleep Inducing Peptide; natural deep sleep without Ambien-class hangover.\nKPV — Gut-specific anti-inflammatory; calms gut lining without systemic immune suppression.\nGHK-Cu — Tissue remodeling; builds collagen scaffolding. Production drops 60-80% with age.\nThymosin Alpha-1 — Immune modulation; supports immune function without suppressing it.\n\nWrite a data-first, evidence-graded article: Recovery Stack for Gabapentin Replacement\n\nAudience: 15M. The problem: gabapentin masks nerve pain without repairing nerve or addressing tissue damage/inflammation. Why the stack maps: ARA repairs nerve, BPC repairs tissue, TB clears inflammation. Novelty: 9/10.\n\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate rat studies from human trials from user reports. No medical claims or treatment promises. Use repair-vs-suppression framing where relevant. register: source_ledger.","response":"{\n  \"slug\": \"recovery-stack-for-gabapentin-replacement\",\n  \"title\": \"Recovery Stack for Gabapentin Replacement\",\n  \"body\": \"## Gabapentin's Limitations\\n\\nGabapentin reduces neuropathic pain signals via calcium channel modulation but does not promote nerve fiber regrowth or resolve underlying tissue damage. [human]\\n\\n## Proposed Recovery Mapping\\n\\nARA-290 targets the innate repair receptor to support small nerve fiber regrowth. [human]\\n\\nBPC-157 promotes angiogenesis and fibroblast activity in tendon, muscle, and gut tissues in animal models. [preclinical]\\n\\nTB-500 (synthetic thymosin beta-4) modulates inflammation and cell migration in tissue repair models. [preclinical]\\n\\n## Evidence Tiers\\n\\n- Human trial data exist for ARA-290 in small fiber neuropathy associated with sarcoidosis, showing improved symptoms and corneal nerve fiber density. [human]\\n- BPC-157 effects are documented exclusively in rat and cell studies for tendon healing and vascularization. [preclinical]\\n- TB-500 data derive from animal models of wound healing and inflammation reduction. [preclinical]\\n- No human trials for the combined stack or direct gabapentin replacement exist. [speculative]\\n\\n## Framing: Repair Versus Suppression\\n\\nThe approach emphasizes addressing nerve structure and tissue integrity rather than solely attenuating pain transmission.\",\n  \"register\": \"source_ledger\",\n  \"claims\": [\n    {\n      \"id\": \"c1\",\n      \"text\": \"Gabapentin reduces neuropathic pain signals via calcium channel modulation but does not promote nerve fiber regrowth or resolve underlying tissue damage.\",\n      \"section\": \"Gabapentin's Limitations\",\n      \"tier\": \"human\",\n      \"source_ids\": [\"s1\"],\n      \"source_status\": \"sourced\",\n      \"why_material\": \"Establishes baseline limitation of current standard approach.\"\n    },\n    {\n      \"id\": \"c2\",\n      \"text\": \"ARA-290 targets the innate repair receptor to support small nerve fiber regrowth.\",\n      \"section\": \"Proposed Recovery Mapping\",\n      \"tier\"","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"24ceac0f15da3e40113825a6908c44b8c62a24e896f8c2bd29abd9537c5ee2c5"},{"ts":"2026-06-29T12:48:01.434Z","model":"kimi/moonshot-v1-8k","action":"collaborate","prompt":"","input":"recovery-stack-gabapentin","response":"I am adding claims that address gaps in the current evidence and naming who claims what, as per the instructions. I am not Grok because I am following the instructions to add claims that are not present in the topology, and I am not inventing new URLs or sources.","tokens_in":1000,"tokens_out":309,"cost":0,"prev":"24ceac0f15da3e40113825a6908c44b8c62a24e896f8c2bd29abd9537c5ee2c5","hash":"937048d350b5d1107c39e9cf42955b6dd240fdcc2d89f638ce510660ddb1c171"},{"ts":"2026-06-29T12:48:31.352Z","model":"system/audit-repair","action":"repair","prompt":"","input":"recovery-stack-gabapentin","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: what_it_is, what_is_known, disclaimer\"],\"after\":[\"missing constitution slots: what_it_is, what_is_known, disclaimer\"]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"937048d350b5d1107c39e9cf42955b6dd240fdcc2d89f638ce510660ddb1c171","hash":"506b21497f190d70d290a6c2e3a3a9320464bc18446322a1b60d65f4447ab186"},{"ts":"2026-06-29T12:48:31.920Z","model":"system/audit-repair","action":"claim","prompt":"","input":"recovery-stack-gabapentin c7","response":"Recovery Stack for Gabapentin Replacement is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"506b21497f190d70d290a6c2e3a3a9320464bc18446322a1b60d65f4447ab186","hash":"34b4c0b92a21a3eace59b71ec1f2cd844066e72b712b49b3898e07b52544a207"},{"ts":"2026-06-29T12:48:31.962Z","model":"system/audit-repair","action":"claim","prompt":"","input":"recovery-stack-gabapentin c8","response":"Per this ledger on Recovery Stack for Gabapentin Replacement: 4 scientific and 0 anecdotal sources are catalogued; 5 preclinical claim(s) summarize animal/cell literature in-catalogue.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"34b4c0b92a21a3eace59b71ec1f2cd844066e72b712b49b3898e07b52544a207","hash":"6d87778ceb071f631ffd9651e9bad6e86628422ffd8591346f891d7da5dfd29d"},{"ts":"2026-06-29T12:48:31.994Z","model":"system/audit-repair","action":"claim","prompt":"","input":"recovery-stack-gabapentin c9","response":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"6d87778ceb071f631ffd9651e9bad6e86628422ffd8591346f891d7da5dfd29d","hash":"e281c0756a61a7018bb41193aefe638782069bae08dfa0345a5d72063957c7b2"},{"ts":"2026-06-29T12:48:32.657Z","model":"system/audit-repair","action":"repair","prompt":"","input":"recovery-stack-gabapentin","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"e281c0756a61a7018bb41193aefe638782069bae08dfa0345a5d72063957c7b2","hash":"26ee948f829def4b89558d8240079d83845af51ecabba7771a4b425ebe71d5fb"},{"ts":"2026-06-29T12:49:13.703Z","model":"gemini/gemini-2.5-flash","action":"collaborate","prompt":"","input":"recovery-stack-gabapentin","response":"I am not Grok; I have strictly adhered to the prompt by adding three tier-honest claims that address explicit gaps in the ledger, specifically focusing on 'what_is_unknown' regarding human data and mechanisms for the discussed compounds. I used only provided source IDs and challenged one claim's tier based on established knowledge implied by its source. I did not invent URLs or provide medical advice.","tokens_in":1515,"tokens_out":570,"cost":0,"prev":"26ee948f829def4b89558d8240079d83845af51ecabba7771a4b425ebe71d5fb","hash":"ae9560ede170322e899c4ec724dbff1a58b19aa89ad46e746c9723f540370d0a"},{"ts":"2026-06-29T13:23:19.014Z","model":"system/audit-repair","action":"repair","prompt":"","input":"recovery-stack-gabapentin","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ae9560ede170322e899c4ec724dbff1a58b19aa89ad46e746c9723f540370d0a","hash":"f5476ac744e5b87e2a7e1e66cda732dc604b9ec6384ea46f5105a229d93d8a33"},{"ts":"2026-06-29T13:23:20.163Z","model":"system/audit-repair","action":"repair","prompt":"","input":"recovery-stack-gabapentin","response":"{\"materialized\":0,\"before\":[],\"after\":[]}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"f5476ac744e5b87e2a7e1e66cda732dc604b9ec6384ea46f5105a229d93d8a33","hash":"7153dfdf75d436739520e113716d033b4a92b1ac9303006dab794e9486d9b6ea"},{"ts":"2026-06-29T14:17:47.623Z","model":"grok/grok-4.3","action":"synthesize_body","prompt":"","input":"recovery-stack-gabapentin","response":"## Regeneration vs degeneration — where this fits\n\nGabapentin reduces how strongly pain signals are felt. It does not heal damaged nerves.  \nPeptides in this ledger are studied for repair pathways. The topic here is whether repair peptides can support tissue recovery where gabapentin only changes signal strength.\n\n## What it is\n\nBPC-157 is studied in animal models for effects on tendon, muscle, and gut tissues.  \nARA-290 is studied in a human trial for small fiber neuropathy symptoms in sarcoidosis patients.  \nTB-500 is studied in animal models for inflammation and cell migration during tissue repair.\n\n## How it works\n\nBPC-157 is linked to increased growth hormone receptor expression in rat tendon fibroblasts. It is also linked to angiogenesis and fibroblast activity in animal tissue models.  \nARA-290 is described as targeting the innate repair receptor. The human trial measured effects on neuropathic symptoms and nerve fiber status.  \nTB-500 is described as modulating inflammation and cell migration in animal repair models.\n\n## Why it would work (logic chain)\n\nIf degeneration outruns regeneration, tissue stays damaged and signals remain active.  \nIf a compound increases blood vessel growth at an injury site, more repair material can reach the tissue.  \nIf a compound supports fibroblast activity, tendon and muscle repair steps can proceed.  \nIf a compound affects small nerve fiber status, neuropathic signals may change because the fiber itself changes.  \nIf a compound affects cell migration and inflammation, the repair sequence has fewer blocks.\n\n## Why people take it\n\nPeople take these compounds when they want to address the tissue state rather than only the signal strength.  \nPeople take them when standard symptom suppression leaves the underlying tissue issue unchanged.\n\n## How many people take it\n\nThe ledger records zero Reddit posts and zero X posts for this topic.  \nNo count of users is available from the sources.\n\n## Evidence inventory\n\nSources total: 4.  \nSt","tokens_in":2739,"tokens_out":791,"cost":0,"prev":"7153dfdf75d436739520e113716d033b4a92b1ac9303006dab794e9486d9b6ea","hash":"8ab77654c964f0b8688e1017c7d75c1357748f80392cdcac46e87d942173eef3"},{"ts":"2026-06-29T15:13:55.000Z","model":"grok-4.3","action":"sources","prompt":"","input":"recovery-stack-gabapentin","response":"5 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"8ab77654c964f0b8688e1017c7d75c1357748f80392cdcac46e87d942173eef3","hash":"1643269cf8252fcfbfbc086e44b21bebab6e24b77f0d6d662f655ab742f106e5"},{"ts":"2026-06-29T15:14:19.918Z","model":"grok-4.3","action":"sources","prompt":"","input":"recovery-stack-gabapentin","response":"4 source(s) added","tokens_in":0,"tokens_out":0,"cost":0,"prev":"1643269cf8252fcfbfbc086e44b21bebab6e24b77f0d6d662f655ab742f106e5","hash":"22e837a451b7623c56684d19c69d2f8d3ec5e2ec3d79dd8c4c059279a026f362"},{"ts":"2026-06-29T19:49:03.780Z","model":"repair","action":"repair","prompt":"","input":"recovery-stack-gabapentin","response":"{\"materialized\":0,\"before\":[\"missing constitution slots: who_claims_what\"],\"after\":[\"missing constitution slots: who_claims_what\"],\"focus_stats\":{\"roles_assigned\":0,\"excluded_sources\":0,\"commercial_sources\":0,\"cut_claims\":0,\"core\":0,\"cycle\":2,\"adjacent\":11}}","tokens_in":0,"tokens_out":0,"cost":0,"prev":"22e837a451b7623c56684d19c69d2f8d3ec5e2ec3d79dd8c4c059279a026f362","hash":"4a0d3e04e5e1fa89c6ddec10ff2438135c8d7458b32ba8e6de012ad5dd0e999c"},{"ts":"2026-06-29T20:59:03.901Z","model":"fill-slots","action":"claim","prompt":"","input":"recovery-stack-gabapentin c23","response":"Recovery Stack for Gabapentin Replacement is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4a0d3e04e5e1fa89c6ddec10ff2438135c8d7458b32ba8e6de012ad5dd0e999c","hash":"48eb0243ad9204e609edd47cf3cbc76550bdf0e3f90d807737bc806473ce2428"},{"ts":"2026-07-17T02:41:13.039Z","model":"owner","action":"voxel_divide","prompt":"","input":"recovery-stack-gabapentin","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"48eb0243ad9204e609edd47cf3cbc76550bdf0e3f90d807737bc806473ce2428","hash":"4c79d3343efca6c42ad63e3e4894afe1494dba8d2ade93f37f3f26130920b9ed"}]}